Oxford Ledge
Search
No licensed closing price on file for ACHV. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.
Achieve Life Sciences, Inc. (NASDAQ: ACHV) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-21 12:41 UTC.
The company is a specialty pharmaceutical firm developing cytisinicline, a naturally occurring compound, to address nicotine dependence through smoking and e-cigarette cessation treatments. Cytisinicline works by binding to nicotinic receptors in the brain as a partial agonist/antagonist, reducing cravings and withdrawal symptoms while diminishing the rewarding effects of nicotine. The company holds an exclusive license from Sopharma AD, which has marketed the compound in Central and Eastern Europe for over two decades, and has developed an improved formulation with flexible dosing options.
Summarized from Achieve Life Sciences, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗
| Valuation | |
| Return on equity | -90.83% |
The company is a specialty pharmaceutical firm developing cytisinicline, a naturally occurring compound, to address nicotine dependence through smoking and e-cigarette cessation treatments.
Achieve Life Sciences, Inc.'s most recent SEC filing on record is a 8-K filed 2026-07-06. All filings link to their SEC EDGAR originals above.
SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-21 12:41 UTC. This page is also available as JSON at /api/data?ticker=ACHV and is emitted with FAQPage structured data for machine reading.
Charts, 10-year financials, peer comparison, screening and portfolio tracking for ACHV and 5,000+ tickers.
Create a free account — keep ACHVGET /api/data?ticker=ACHV
This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt